Amgen, Servier Extend Heart Failure Collaboration

Under Amgen and Servier’s cardiovascular collaboration, Servier has exercised its option to commercialize omecamtiv mecarbil in chronic heart failure in Europe, and the Commonwealth of Independent States, including Russia. Also, the companies omecamtiv mecarbil Phase III development program will move forward in collaboration with Cytokinetics.

Servier will make a $10 million option exercise payment, as well as future milestone and royalty payments to Amgen. Servier will assume a share of the development costs.

“We are very pleased to strengthen our collaboration with Servier and for the continued advancement of the novel cardiac myosin activator omecamtiv mecarbil,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “We are working closely with our research collaborators and regulators on the Phase 3 outcomes study for omecamtiv mecarbil and look forward to assessing the potential of this unique therapy to benefit patients with chronic heart failure worldwide.”

Results from a Phase II trial evaluating omecamtiv mecarbil in patients with chronic heart failure, met its primary pharmacokinetic objective and demonstrated significant improvement in all pre-specified secondary measures of cardiac function.